Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: GlobeNewswire
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative to the Company for ADP-A2M4 for the treatment of synovial sarcoma. PRIME access provides enhanced scientific and regulatory support by the EMA to developers of medicines with the potential to significantly address unmet medical needs. “We are thrilled that the EMA has acknowledged the potential of ADP-A2M4 to address an unmet medical need for more effective treatment options for patients with advanced synovial sarcoma,” said Dennis Williams, PharmD, Adaptimmune’s Senior Vice President, Late Stage Development. “Access to the enhanced EMA support and guidance offered in the PRIME scheme will facilitate the development of ADP-A2M4 to ensure this important medicine reaches patients with sarcoma as early as possible.” Access to th
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]Yahoo! Finance
- Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]Yahoo! Finance
- Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]Seeking Alpha
- Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]Yahoo! Finance
- Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/22/24 - Form ARS
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- ADAP's page on the SEC website